title: Serum antibody response in adult volunteers elicited by injection of Streptococcus pneumoniae type 12F polysaccharide alone or conjugated to diphtheria toxoid.
abstract: Conjugates of an uronic acid-containing capsular polysaccharide (CP), pneumococcous type 12F (Pn12F) bound to diphtheria toxoid (DT), were studied for safety and immunogenicity in adult volunteers. In mice, these conjugates, prepared with the same lot of DT and Pn12F-40234-006, a homogenous CP of high molecular weight, or Pn12-812408, a polydisperse CP with lower-molecular-weight material, were more immunogenic than the Pn12F alone and had T-cell dependent properties (A. Fattom, W. F. Vann, S.C. Szu, A. Sutton, X. Li, B. Bryla, G. Schiffman, J. B. Robbins, and R. Schneerson, Infect. Immun. 56:2292-2298, 1988). Adult volunteers, randomized into three groups, were injected either with one of these two conjugates or with Pnu-Imune, the 23 valent pneumococcus vaccine containing 25 micrograms of Pn12F as one of its components. Volunteers were injected two times, 4 weeks apart, with the Pn12F-DT conjugates and once with the Pnu-Imune. Side reactions following injection of the conjugates of Pnu-Imune were mild and short-lived. At 4 weeks and at 7 months after the first injection, higher levels of Pn12F antibodies were found in the volunteers injected with the conjugates than in the Pnu-Imune group (P less than 0.001). The conjugate prepared with the higher-molecular-weight Pn12F elicited higher levels of antibodies than the conjugate prepared with a lower-molecular-weight Pn12F preparation (P = 0.05). Both conjugates elicited about a 13-fold rise in DT antibodies.
authors.affiliation: Laboratory of Developmental and Molecular Immunity, National Institute of Child Health and Human Development, Bethesda, Maryland 20892.
authors.forename: A
authors.initials: A
authors.lastname: Fattom
authors.forename: C
authors.initials: C
authors.lastname: Lue
authors.forename: S C
authors.initials: SC
authors.lastname: Szu
authors.forename: J
authors.initials: J
authors.lastname: Mestecky
authors.forename: G
authors.initials: G
authors.lastname: Schiffman
authors.forename: D
authors.initials: D
authors.lastname: Bryla
authors.forename: W F
authors.initials: WF
authors.lastname: Vann
authors.forename: D
authors.initials: D
authors.lastname: Watson
authors.forename: L M
authors.initials: LM
authors.lastname: Kimzey
authors.forename: J B
authors.initials: JB
authors.lastname: Robbins
mesh_terms: D000293:Adolescent; D000328:Adult; D000907:Antibodies, Bacterial / Q000096:biosynthesis*; D001428:Bacterial Vaccines / Q000276:immunology* / Q000633:toxicity; D002240:Carbohydrate Sequence; D003432:Cross-Linking Reagents; D004168:Diphtheria Toxoid / Q000276:immunology; D005260:Female; D006801:Humans; D008297:Male; D008969:Molecular Sequence Data; D011135:Polysaccharides, Bacterial / Q000276:immunology*; D013296:Streptococcus pneumoniae / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000276:immunology / Q000633:toxicity
chemical_list: D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines; D003432:Cross-Linking Reagents; D004168:Diphtheria Toxoid; D011135:Polysaccharides, Bacterial; C064834:Streptococcus pneumoniae type 12F polysaccharide; D014614:Vaccines, Synthetic